Oka Michiko, Ueda Makoto, Oyama Tatsuya, Kyotani Junko, Tanaka Mitsushi
Research Laboratories, Nippon Shinyaku Co., Ltd., Minami-ku, Kyoto 601-8550, Japan.
Prostate. 2009 Sep 15;69(13):1404-10. doi: 10.1002/pros.20985.
Anti-inflammatory medications have been used for the treatment of chronic prostatitis. The phytotherapeutic agent Eviprostat, a popular treatment for benign prostatic hyperplasia in Japan and Germany, has antioxidant and anti-inflammatory activity. We investigated the effects of the phytotherapeutic agent Eviprostat on prostate inflammation induced in castrated rats by the injection of 17beta-estradiol.
Ten-month-old male Wistar rats were divided into five groups. Nonbacterial prostatitis was experimentally induced in groups 2-5 by castration followed by daily subcutaneous injection of 17beta-estradiol for 30 days. The rats were orally administered 0.1% Tween-80 (group 2), low-dose Eviprostat (group 3), high-dose Eviprostat (group 4), or cernitin pollen extract (group 5) for the last 2 weeks of 17beta-estradiol administration. Sham-operated rats (group 1) were orally administered 0.1% Tween-80. On the 31st day after surgery, the weight of the prostate and the levels of prostatic proinflammatory cytokines as well as the oxidative-stress marker malondialdehyde were determined and histological alterations noted.
Experimentally induced nonbacterial prostatitis led to a significant decrease in prostate weight and increases in malondialdehyde and proinflammatory cytokine levels. Eviprostat significantly suppressed the increases in malondialdehyde and cytokine levels without affecting prostate weight. Histologically, nonbacterial prostatitis was evident in the lateral lobe of the prostate, and Eviprostat treatment significantly suppressed the severity of the lesion.
Eviprostat, which has effective antioxidant and anti-inflammatory activities in the prostate, may be useful for the clinical treatment of chronic prostatitis. These activities of Eviprostat may also contribute to the amelioration of prostate inflammation in BPH patients. Prostate 69: 1404-1410, 2009. (c) 2009 Wiley-Liss, Inc.
抗炎药物已被用于治疗慢性前列腺炎。植物治疗剂爱普列特，在日本和德国是治疗良性前列腺增生的常用药物，具有抗氧化和抗炎活性。我们研究了植物治疗剂爱普列特对注射17β -雌二醇诱导去势大鼠前列腺炎症的影响。
将10月龄雄性Wistar大鼠分为五组。第2 - 5组通过去势并每日皮下注射17β -雌二醇30天，实验性诱导非细菌性前列腺炎。在给予17β -雌二醇的最后2周，大鼠口服0.1%吐温80（第2组）、低剂量爱普列特（第3组）、高剂量爱普列特（第4组）或舍尼通花粉提取物（第5组）。假手术大鼠（第1组）口服0.1%吐温80。术后第31天，测定前列腺重量、前列腺促炎细胞因子水平以及氧化应激标志物丙二醛，并记录组织学改变。
实验性诱导的非细菌性前列腺炎导致前列腺重量显著降低，丙二醛和促炎细胞因子水平升高。爱普列特显著抑制丙二醛和细胞因子水平的升高，而不影响前列腺重量。组织学上，前列腺外侧叶可见明显的非细菌性前列腺炎，爱普列特治疗显著减轻了病变的严重程度。
爱普列特在前列腺中具有有效的抗氧化和抗炎活性，可能对慢性前列腺炎的临床治疗有用。爱普列特的这些活性也可能有助于改善良性前列腺增生患者的前列腺炎症。《前列腺》69: 1404 - 1410, 2009。(c) 2009威利 - 利斯公司。
